With the advent of next-generation sequencing technologies, there has been a dramatic increase in the availability of paired clinical and transcriptomic data in a variety of disease states. For basic science researchers, this has provided a valuable opportunity for querying the impact of the transcript levels of a gene on disease survival in humans. However, there are a multitude of methodological and technical considerations to evaluate before embarking on these analyses. Herein, we provide a brief description of statistical considerations involved in these analyses, geared toward basic scientists who may not necessarily routinely use such statistical models as part of their studies.
Keywords: Kaplan–Meier; RNAseq; survival.